BEGIN:VCALENDAR
PRODID: University of Exeter
VERSION:2.0
BEGIN:VTIMEZONE
TZID:Europe/London
X-LIC-LOCATION:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20160411T153000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20160411T153000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
END:STANDARD
END:VTIMEZONE
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY; CHARSET=UTF-8 :"Does Replication help with Experimental Biases in Clinical Trials?" Prof David Teira (UNED, Madrid)
UID:exeter_event_5034
URL:http://www.exeter.ac.uk/events/details/?event=5034
DTSTART;VALUE=DATE:20160411T153000
DTEND;VALUE=DATE:20160411T170000
X-MICROSOFT-CDO-ALLDAYEVENT:FALSE
ORGANIZER: MAILTO:
ATTACH: http://www.exeter.ac.uk/events/details/?event=5034
DTSTAMP:20160310T151136
LOCATION:Byrne House
DESCRIPTION; CHARSET=UTF-8 :During the last decade, a replication crisis has been detected in many experimental fields, and, in particular, in drug testing in clinical trials. Experimental outcomes published in top journals do not stand the test of reproduction.  A widespread interpretation of this crisis puts the blame on the experimenters’ financial biases. Clinical trials are regulatory experiments in which a treatment may gain or not market access: the financial stakes for the sponsor of the development of the treatment are high. Therefore, the sponsor may put direct or indirect pressure on the experimenter to obtain a positive outcome. Often, once this pressure is relaxed, in further replications of the trial, the original positive outcome vanishes. The implicit assumption in this interpretation is that, once we correct for the sponsor biases, trials will become more replicable than they actually are.

We want to contest this interpretation of the replication crisis with an analysis of the concept of experimental bias in clinical trials. We will focus on the biases that may flaw the design and conduct of the test. Our basic claim is that replication in experiments is only valuable once the experimenters have agreed on a standardized intervention and a list of debiasing controls to be implemented in the trial. Replicability mainly helps us in controlling for unintended deviations from the protocol, once the relevant debiasing procedures have been implemented. But the major problems with trials lie elsewhere: either in improperly debiased tests or in trials with clinically irrelevant variables. Against a widespread intuition, we will defend that the outcomes in these latter trials are perfectly replicable. If we want better trials, fostering replicability (good as it may be) is perhaps not helpful in itself.http://www.exeter.ac.uk/events/details/?event=5034
SEQUENCE:0
PRIORITY:5
CLASS:
STATUS:CONFIRMED
TRANSP:TRANSPARENT
X-MICROSOFT-CDO-IMPORTANCE:1
X-Microsoft-CDO-BUSYSTATUS:FREE
X-MICROSOFT-CDO-INSTTYPE:0
X-Microsoft-CDO-INTENDEDSTATUS:FREE
END:VEVENT
END:VCALENDAR